220 related articles for article (PubMed ID: 19160853)
1. [Interferon alpha-2b modified with polyethylene glycol].
Wu Y; Zhai Y; Lei J; Ma G; Su Z
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
[TBL] [Abstract][Full Text] [Related]
2. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
Ramon J; Saez V; Baez R; Aldana R; Hardy E
Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
[TBL] [Abstract][Full Text] [Related]
3. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
[TBL] [Abstract][Full Text] [Related]
4. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
[TBL] [Abstract][Full Text] [Related]
5. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
Pokholenko IaA; Porubleva LV; Dubeĭ IIa; Rebriev AV; Sutugina LP; Gromovoĭ TIu; Pokrovskiĭ VA; Obolenskaia MIu; Chernykh SI
Ukr Biokhim Zh (1999); 2008; 80(6):92-100. PubMed ID: 19351063
[TBL] [Abstract][Full Text] [Related]
6. Identification of the major positional isomer of pegylated interferon alpha-2b.
Wang YS; Youngster S; Bausch J; Zhang R; McNemar C; Wyss DF
Biochemistry; 2000 Sep; 39(35):10634-40. PubMed ID: 10978146
[TBL] [Abstract][Full Text] [Related]
7. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
[TBL] [Abstract][Full Text] [Related]
8. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
[TBL] [Abstract][Full Text] [Related]
9. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
11. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
12. Pegylated IFNs for chronic hepatitis C: an update.
Grace MJ; Cutler DL; Bordens RW
Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
[TBL] [Abstract][Full Text] [Related]
13. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the ion exchange chromatography for matrix-assisted PEGylation and purification of consensus interferon.
Bajwa F; Ahmed N; Khan MA; Azam F; Akram M; Tahir S; Zafar AU
Biotechnol Appl Biochem; 2020 Mar; 67(2):196-205. PubMed ID: 31589775
[TBL] [Abstract][Full Text] [Related]
16. [Preparation and characterization of mono PEGylated recombinant human interferon omega].
Liu H; Cheng YG; Pan HC; Xu B; Peng L; Yang HT; Guo W
Yao Xue Xue Bao; 2012 Mar; 47(3):393-8. PubMed ID: 22645765
[TBL] [Abstract][Full Text] [Related]
17. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.
Lee BK; Kwon JS; Kim HJ; Yamamoto S; Lee EK
Bioconjug Chem; 2007; 18(6):1728-34. PubMed ID: 17941681
[TBL] [Abstract][Full Text] [Related]
18. A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.
Imada T; Moriya K; Uchiyama M; Inukai N; Hitotsuyanagi M; Masuda A; Suzuki T; Ayukawa S; Tagawa YI; Dohmae N; Kohara M; Yamamura M; Kiga D
ACS Synth Biol; 2018 Nov; 7(11):2537-2546. PubMed ID: 30277749
[TBL] [Abstract][Full Text] [Related]
19. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats.
Loftis JM; Wall JM; Pagel RL; Hauser P
Psychoneuroendocrinology; 2006 Nov; 31(10):1289-94. PubMed ID: 17049181
[TBL] [Abstract][Full Text] [Related]
20. Pegylation of interferon alfa: structural and pharmacokinetic properties.
Pedder SC
Semin Liver Dis; 2003; 23 Suppl 1():19-22. PubMed ID: 12934164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
